Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.59 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19070659 | 0.93 | F2 (0.56) | PBRM1F2PLGPRSS1PRSS2 | |
| SCHEMBL7133352 | 0.89 | F2 (0.48) | PBRM1F2PLGPRSS1PRSS2 | |
| Aniline SCHEMBL28205031 | 0.86 | TSHR (0.58) | PBRM1F2MAOAMEN1KMT2A | |
| SCHEMBL28205030 | 0.84 | PBRM1 (0.47) | PBRM1F2PLGPRSS1PRSS2 | |
| SCHEMBL814654 | 0.84 | MEN1 (0.52) | PBRM1KDRMAOAMEN1KMT2A | |
| SCHEMBL12326742 | 0.82 | PBRM1 (0.57) | PBRM1F2PLGPRSS1PRSS2 | |
| SCHEMBL21811989 | 0.81 | MEN1 (0.50) | PBRM1KDRMAOAMEN1KMT2A | |
| SCHEMBL9823021 | 0.79 | MEN1 (0.54) | F2PRSS1PRSS3MAOAMEN1 | |
| Benzene SCHEMBL28340939 | 0.78 | MEN1 (0.61) | F2MAOAMEN1KMT2ACYP3A4 | |
| Benzene SCHEMBL9731493 | 0.78 | MEN1 (0.61) | F2MAOAMEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708332-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11685721-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230056538-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-02-23 | — | — | US | disclosed |
| US-11203574-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-11192861-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210047276-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-02-18 | — | — | US | disclosed |
| US-20210047275-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-02-18 | — | — | US | disclosed |
| US-10633345-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-10562912-B2 | Heterocyclic derivatives and use thereof | C&C RESEARCH LABORATORIES (KR) | 2020-02-18 | — | — | US | disclosed |
| EP-3004057-B1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STAT 3 INHIBITORS | C&C RES LAB (KR) | 2018-07-25 | — | — | EP | disclosed |
| US-20160108056-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2016-04-21 | — | — | US | disclosed |
| EP-3004057-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C Research Laboratories (KR) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014196793-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11203574-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | PBRM1 4339/4885F2 24/4885PLG 32/4885 |
| US-11708332-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | PBRM1 4339/4885F2 24/4885PLG 32/4885 |
| US-11192861-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | PBRM1 4339/4885F2 24/4885PLG 32/4885 |
| US-20160108056-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | STAT3, JAK2, STAT5A | PBRM1 916/4885F2 2629/4885PLG 3479/4885 |
| US-20210047275-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | PBRM1 4339/4885F2 24/4885PLG 32/4885 |
| US-20210047276-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | PBRM1 4339/4885F2 24/4885PLG 32/4885 |
| US-20230056538-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | PBRM1 4230/4885F2 29/4885PLG 32/4885 |
| US-10633345-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | PBRM1 4429/4885F2 28/4885PLG 26/4885 |
| US-10562912-B2 | Heterocyclic derivatives and use thereof | STAT3, JAK2, STAT5A | PBRM1 916/4885F2 2629/4885PLG 3479/4885 |
| US-11685721-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | PBRM1 4230/4885F2 29/4885PLG 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.